France Cell & Gene Therapy Cold Chain Logistics Market to Grow with a CAGR of 14.22% through 2028
According to
TechSci Research report, “France Cell & Gene Therapy Cold Chain
Logistics Market – By Region, Competition, Forecast and Opportunities, 2028”,
the France Cell & Gene Therapy Cold Chain Logistics Market stood at USD 83.63
million in 2022 and is anticipated to grow with a CAGR of 14.22% in the
forecast period, 2024-2028. This can be attributed to the emergence of advanced
therapies. Biotechnology has fueled the emergence of advanced therapies, such
as CRISPR-based gene editing and CAR-T cell therapies. These therapies hold
immense promise for treating previously incurable diseases. However, their
delicate nature requires stringent temperature controls throughout the supply
chain. The evolution of these advanced therapies is intricately linked to the
parallel development of cold chain logistics solutions capable of preserving
their potency and viability.
Furthermore, the
digitalization of documentation and compliance processes is streamlining
regulatory adherence in the logistics sector. Electronic data management
systems, blockchain technology, and digital platforms for documentation are
becoming increasingly prevalent. These advancements not only improve efficiency
but also contribute to enhanced traceability and transparency throughout the
supply chain.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"France Cell & Gene Therapy Cold Chain Logistics Market”
The cell and
gene therapy sector in France has witnessed a growing demand for efficient cold
chain logistics solutions. These logistics play a crucial role in maintaining
the integrity and viability of sensitive biological materials throughout the
supply chain, ensuring the safe and effective delivery of cell and gene
therapies.
The market for
cell and gene therapy cold chain logistics in France has experienced notable
growth, driven by advancements in biotechnology and an increasing number of
clinical trials and commercialization of these innovative therapies.
The France Cell
& Gene Therapy Cold Chain Logistics Market is segmented into component, services offered,
mode of transportation, holding temperature range, end user, regional
distribution, and company.
Based on its component, Cryogenic
shippers are poised to dominate the Cell & Gene Therapy Cold Chain
Logistics Market in France for several compelling reasons. The intricate and
sensitive nature of cell and gene therapies demands a highly precise and stable
temperature-controlled environment, and cryogenic shippers excel in providing
and maintaining ultra-low temperatures essential for preserving the integrity
of these advanced therapies. Their ability to maintain consistent temperature
levels during transportation ensures the viability and efficacy of the
biological materials involved in these therapies. Additionally, the increasing
adoption of cell and gene therapies in France necessitates a reliable and
efficient cold chain logistics system, where cryogenic shippers play a pivotal
role. The advanced technology and stringent temperature control features of
cryogenic shippers align perfectly with the stringent regulatory requirements
and quality standards governing the transportation of cell and gene therapy
products. As the demand for these innovative therapies continues to rise, the
dominance of cryogenic shippers in the French market is poised to grow,
ensuring the seamless and secure delivery of these life-changing treatments.
Based on end
user, Pharmaceutical and biotechnology companies are positioned to emerge as
dominant end-users in the Cell & Gene Therapy Cold Chain Logistics Market
in France due to their pivotal role in driving advancements and innovation in
the field. The intricate nature of cell and gene therapies requires substantial
expertise, infrastructure, and investment, elements that pharmaceutical and
biotechnology companies possess in abundance. These entities are at the
forefront of developing cutting-edge therapies and are instrumental in bringing
them from the research stage to commercialization. Given their extensive
involvement in the production and distribution of cell and gene therapies,
pharmaceutical and biotechnology companies have a vested interest in
establishing robust cold chain logistics systems. Their commitment to ensuring
the integrity, safety, and efficacy of these therapies positions them as key
stakeholders in shaping the logistics landscape. As the demand for personalized
and advanced therapies continues to escalate, the dominance of pharmaceutical
and biotechnology companies as end-users in the French market is set to grow,
reflecting their central role in driving the success and accessibility of cell
and gene therapies.
Major
companies operating in France Cell & Gene Therapy Cold Chain Logistics
Market are:
- World Courier Lyon
- United Parcel Service France SAS
- Catalent, Inc.
- BioLife Solutions, Inc.
- Cryoport, Inc.
- Thermo Fisher Scientific (FEI France SAS)
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The future of
France's Cell & Gene Therapy Cold Chain Logistics Market is marked by
innovation, collaboration, and a commitment to meeting the unique challenges
posed by these groundbreaking therapies. As the industry embraces advanced
technologies, sustainable practices, and adapts to evolving regulatory
landscapes, the logistics infrastructure supporting cell and gene therapies is
poised to become more resilient and efficient. Navigating the upcoming trends
will be essential for ensuring the continued success of cell and gene therapy
logistics in France's dynamic biopharmaceutical ecosystem,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“France Cell & Gene Therapy Cold Chain
Logistics Market By Component
(Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain
Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others
{Shipment Containers, Reusable Boxes, etc.}), By Services Offered
(Transportation, Storage, Packaging), By Mode of Transportation (Air, Ground,
Water), By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others
{Deep Freezers, Dry Ice, etc.}), By End User (Pharmaceutical &
Biotechnology Companies, Academic & Research Institutes, Others), By
Region, By Competition Forecast & Opportunities, 2018-2028F”,
has evaluated the future growth potential of France Cell & Gene Therapy
Cold Chain Logistics Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in France Cell
& Gene Therapy Cold Chain Logistics Market.
Contact
TechSci
Research LLC
420 Lexington
Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com